This study in healthy volunteers will provide a basis for evaluation of TRL345 as a first in human study, specifically, important safety, tolerability, and pharmacokinetic data, and provide serum samples for ex vivo studies of concentration-dependent antiviral activity to support the dose selection for as well as design and conduct of a clinical study in transplant patients.

Start Date14 Sep 2023

Sponsor / Collaborator

Trellis Bioscience, Inc.

[+1]

100 Clinical Results associated with HCMV gp

100 Translational Medicine associated with HCMV gp

0 Patents (Medical) associated with HCMV gp

Literatures (Medical) associated with HCMV gp

01 Sep 2022·British Journal of OphthalmologyQ2 · MEDICINE

Polymorphisms of the cytomegalovirus glycoprotein B genotype in patients with Posner-Schlossman syndrome

Q2 · MEDICINE

Article

Author: Zhai, Ruyi ; Sun, Xinghuai ; Sheng, Qilian ; Wang, Zhujian ; Fan, Xintong ; Kong, Xiangmei

AimsThe aim of this observational study was to report the distribution of glycoprotein B (gB) genotypes in the eyes of cytomegalovirus (CMV) positive patients with Posner-Schlossman syndrome (PSS), and to investigate their clinical characteristics and outcomes.MethodsWe collected aqueous humour samples from 165 patients clinically diagnosed with PSS between 2017 and 2019. PCR was performed to analyse the CMV DNA and identify the gB genotypes in the samples. Clinical characteristics and responses to antiviral treatment were compared among patients with different gB genotypes.ResultsCMV DNA was detected in 94 (56.97%) of the 165 aqueous humour specimens analysed. Owing to the quantity requirement for CMV gB genotype analysis, results could be obtained from only 14 specimens. CMV gB type 1 was detected in 11 samples (78.6%), whereas CMV gB type 3 was detected in three samples (21.4%). No other gB genotypes or mixed genotypes were detected. Overall, 9.1% (1/11) of the patients in the gB type 1 group and 66.7% (2/3) of the patients in the gB type 3 group had bilateral attacks (p=0.093). The concentration of anti-CMV immunoglobulin G (IgG) in the type 1 group was 0.94±0.79 s/co (ratio of aqueous humour CMV IgG/serum CMV IgG to aqueous humour albumin concentration/serum albumin concentration), whereas that in the type 3 group was 0.67±0.71 s/co.ConclusionGenotype 1 was the most prevalent genotype in the aqueous humour of CMV-infected patients with PSS. Bilateral attack was predominant among patients with gB genotype 3. CMV gB gene may be related to the pathogenicity of CMV virus strain in patients with PSS.

05 Mar 2021·Science AdvancesQ1 · CROSS-FIELD

Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion

Q1 · CROSS-FIELD

ArticleOA

Author: Yang, Xinzhen ; Che, Ye ; Han, Seungil ; Liu, Yuhang ; Dormitzer, Philip R. ; Heim, Kyle P. ; Chi, Xiaoyuan ; Qiu, Xiayang

Prefusion human cytomegalovirus glycoprotein B structure reveals the structural basis for membrane fusion.

01 Jul 2018·Journal of Pharmaceutical and Biomedical AnalysisQ3 · MEDICINE

A rapid magnetic particle-based enzyme immunoassay for human cytomegalovirus glycoprotein B quantification

Q3 · MEDICINE

Article

Author: Pires, F ; Castillo, Juan R ; Arcos-Martinez, M Julia ; Vidal, Juan C ; Dias-Cabral, A Cristina

Human cytomegalovirus (HCMV) is a herpes virus that can cause severe infections. Still, the available methods for its diagnostic have the main disadvantage of requiring long time to be performed. In this work, a simple magnetic particle-based enzyme immunoassay (mpEIA) for the quantification of glycoprotein B of Human cytomegalovirus (gB-HCMV) in urine samples is proposed. The immunosensor scheme is based on the analyte protein gB-HCMV sandwiched between a primary monoclonal antibody, (MBs-PrG-mAb1), and a secondary anti-gB-HCMV antibody labelled with Horseradish peroxidase (Ab2-HRP) to allow spectrophotometric detection. The mpEIA analytical performance was tested in urine samples, showing a linear dependence between gB-HCMV concentration and the absorbance signal at 450 nm in a range of concentrations from 90 to 700 pg mL^-1. The calculated detection limits for gB-HCMV were 90 ± 2 pg mL^-1 and the RSD was about 6.7% in urine samples. The immunosensor showed good selectivity against other viruses from Herpesviridae family, namely varicella zoster and Epstein Barr viruses. The recoveries of spiked human urine samples at 0.30-0.50 ng mL^-1 concentration levels of gB-HCMV ranged between 91 to 105%. The proposed mpEIA method was validated following the guidelines of the European Medicines Agency (EMEA-2014), and allows rapid, successful and easy quantification of gB-HCMV in urine samples.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

HCMV gp

Basic Info

Related

Analysis